- Home
- USEA vs BIAF Comparison
USEA vs BIAF Comparison
Compare USEA & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEA
- BIAF
- Stock Information
- Founded
- USEA 2004
- BIAF 2014
- Country
- USEA Greece
- BIAF United States
- Employees
- USEA N/A
- BIAF N/A
- Industry
- USEA Marine Transportation
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- USEA Consumer Discretionary
- BIAF Health Care
- Exchange
- USEA Nasdaq
- BIAF Nasdaq
- Market Cap
- USEA 10.5M
- BIAF 12.2M
- IPO Year
- USEA N/A
- BIAF 2022
- Fundamental
- Price
- USEA $1.57
- BIAF $0.29
- Analyst Decision
- USEA
- BIAF Hold
- Analyst Count
- USEA 0
- BIAF 1
- Target Price
- USEA N/A
- BIAF N/A
- AVG Volume (30 Days)
- USEA 23.4K
- BIAF 2.0M
- Earning Date
- USEA 08-12-2025
- BIAF 08-13-2025
- Dividend Yield
- USEA 2.56%
- BIAF N/A
- EPS Growth
- USEA N/A
- BIAF N/A
- EPS
- USEA N/A
- BIAF N/A
- Revenue
- USEA $42,595,000.00
- BIAF $8,809,228.00
- Revenue This Year
- USEA N/A
- BIAF N/A
- Revenue Next Year
- USEA $11.62
- BIAF $20.00
- P/E Ratio
- USEA N/A
- BIAF N/A
- Revenue Growth
- USEA N/A
- BIAF 78.40
- 52 Week Low
- USEA $1.00
- BIAF $0.16
- 52 Week High
- USEA $2.78
- BIAF $2.48
- Technical
- Relative Strength Index (RSI)
- USEA 53.73
- BIAF 44.33
- Support Level
- USEA $1.56
- BIAF $0.31
- Resistance Level
- USEA $1.61
- BIAF $0.35
- Average True Range (ATR)
- USEA 0.08
- BIAF 0.04
- MACD
- USEA -0.01
- BIAF -0.00
- Stochastic Oscillator
- USEA 67.70
- BIAF 22.48
About USEA United Maritime Corporation
United Maritime Corp operates as a shipping company currently specializing in the seaborne transportation of dry bulk commodities. It currently operates one LR2 tanker vessel and three Capesize dry bulk vessels, two Kamsarmax dry bulk vessels, and three Panamax dry bulk vessels, with an aggregate cargo-carrying capacity of approximately 1,004,289 dwt.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.